Hematology/Oncology

Top Story

Dabrafenib plus trametinib demonstrates long-term tolerability in BRAF V600–mutated melanoma

March 24, 2017

NEW YORK — Extended treatment with dabrafenib plus trametinib demonstrated consistent tolerability profiles in patients with BRAF V600–mutant melanoma, according to a pooled analysis presented at HemOnc Today Melanoma and Cutaneous Malignancies.

The phase 3 COMBI-d and COMBI-v studies — designed to evaluate dabrafenib (Tafinlar, Novartis), a BRAF kinase inhibitor, plus trametinib (Mekinist, Novartis), a MEK inhibitor — showed tolerability and efficacy with the combination with a median follow-up of 20.2 months.

Meeting News

Strategies to detect immune-based biomarkers evolving for melanoma treatment

March 24, 2017
NEW YORK — Several blood- and tissue-based assays are in development to identify appropriate treatment options for patients with melanoma, according to a speaker…

GOP, Trump pull AHCA due to lack of support

March 24, 2017
Reportedly acting on orders from President Donald J. Trump, House Republican leaders today again postponed a vote that would have overhauled the nation’s health…
Meeting News

Choosing adjuvant melanoma therapy remains ‘controversial, tough’

March 24, 2017
NEW YORK — Interferon and ipilimumab are options for the adjuvant treatment of many patients with melanoma, but data are lacking comparing these two agents…
Meeting NewsVideo

VIDEO: Artificial intelligence may be feasible for melanoma diagnosis

March 24, 2017
NEW YORK — Smartphone applications and other forms of artificial intelligence have the potential to be valuable tools for the detection of melanoma, Allan C
More News Headlines »
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News

VIDEO: Resurgence of cutaneous radiation therapy for skin cancer

March 21, 2017
More »
Featured
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement